Abstract
Systemic administration of swainsonine, an indolizidine alkaloid, inhibits the experimental metastasis of B16-F10 murine melanoma cells. This activity can be attributed primarily to swainsonine-mediated enhancement of host natural killer cell activity. As one next step towards investigating the potential therapeutic utility of this drug, its efficacy in enhancing host survival in the same B16-F10 model system has been assessed. In studies employing intravenously injected tumor cells, pretreatment of mice with swainsonine-containing drinking water provided a reproducible protective effect for the host. This prolongation of survival was substantially enhanced when swainsonine was administered in combination with either of two other immunomodulators, polyinosinic: cytidylic acid (poly-IC) or interleukin-2. In studies in which combinations of these agents were administered after intravenous injection of tumor cells, or after subcutaneous implantation, a greatly reduced effect on host survival was observed. However, when used in combination with cyclophosphamide (to block the effects of suppressor T cells), swainsonine did increase mean survival time. The implications of these results for the use of swainsonine in treatment of metas...Continue Reading
References
Oct 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·R L CavalieriS Pestka
Apr 15, 1975·International Journal of Cancer. Journal International Du Cancer·L M van PuttenM Füzy
Jan 1, 1986·Springer Seminars in Immunopathology·A Hollinshead
Jan 1, 1989·Pharmacology & Therapeutics·M J Humphries, K Olden
Jan 1, 1988·Journal of Cancer Research and Clinical Oncology·G PulvererG Uhlenbruck
Mar 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·M J HumphriesK Olden
Jan 30, 1987·Biochemical and Biophysical Research Communications·R DeSantisM C Glick
Jan 29, 1988·Biochemical and Biophysical Research Communications·S L WhiteK Olden
Mar 15, 1988·Biochemical and Biophysical Research Communications·T L Bowlin, P S Sunkara
Jan 1, 1987·Annual Review of Biochemistry·A D Elbein
Sep 19, 1986·Science·S A RosenbergR Lafreniere
Jan 1, 1986·Annual Review of Immunology·S A Rosenberg, M T Lotze
Jan 1, 1987·Cancer Metastasis Reviews·J W Dennis, S Laferte
Jul 1, 1985·The Journal of Antibiotics·T KinoH Imanaka
Nov 1, 1972·Computer Programs in Biomedicine·E T Lee, M M Desu
Sep 1, 1967·Proceedings of the National Academy of Sciences of the United States of America·A K FieldM R Hilleman
Mar 30, 1984·Science·S A RosenbergD F Mark
Oct 31, 1983·FEBS Letters·D J AbrahamA Dell
Jun 29, 1984·Science·A WangD F Mark
Apr 9, 1982·Science·R J Molyneux, L F James
Citations
Nov 5, 2008·Archives of Pharmacal Research·B S ChaeJ H Kim
Jan 1, 1991·Pharmacology & Therapeutics·K OldenS L White
Jul 10, 1999·Bioorganic & Medicinal Chemistry·G G PerroneI J McFarlane
Aug 30, 2003·International Immunopharmacology·Oladipo A OredipeRajagopalan Sridhar
Jan 1, 1994·Cancer Investigation·R C Turowski, P L Triozzi
Oct 4, 1993·Carbohydrate Research·M S KangS P Sunkara
Oct 24, 2007·Phytochemistry·Russell J MolyneuxLynn F James
Aug 26, 1998·The Journal of Biological Chemistry·W H TaylorJ D Esko
Jan 1, 1992·Pigment Cell Research·K OldenS L White
Dec 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Rodney MorganBaiyong Li
May 27, 2004·Journal of Agricultural and Food Chemistry·Lynn F JamesRussell J Molyneux